Exagen Analyst Price Targets - Benzinga

Exagen Inc

XGNNASDAQ

Trade with Public

Trade with Public

$7.47

0.202.75%

Ult. Agg.: Oct 26, 4:00 PM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Exagen Analyst Price Targets - Benzinga

Exagen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Exagen (XGN).

Price Target Range — 9 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$10Upside to Avg. PT+30.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$9→$11
Oct 13, 2026	TD Cowen	Dan Bergstrom	PT Raise	Buy	$10→$11
Aug 5, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$8→$10
Aug 5, 2026	B. Riley Securities	Anderson Schock	PT Raise	Buy	$8→$12
Aug 5, 2026	BTIG	Mark Massaro	PT Raise	Buy	$8→$9
Jun 25, 2026	Roth Capital	Max Masucci	Initiate	Buy	$8
May 12, 2026	BTIG	Mark Massaro	PT Cut	Buy	$9→$8
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$10→$8
Mar 11, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$15→$10
Mar 11, 2026	Craig-Hallum	John Wilkin	PT Cut	Buy	$12→$10
Mar 11, 2026	Keybanc	Paul Knight	PT Cut	Overweight	$15→$10
Mar 10, 2026	BTIG	Mark Massaro	PT Cut	Buy	$10→$9
Feb 24, 2026	TD Cowen	Dan Brennan	PT Cut	Buy	$13→$10
Feb 17, 2026	BTIG	Mark Massaro	PT Cut	Buy	$15→$10
Jan 30, 2026	B. Riley Securities	Anderson Schock	PT Cut	Buy	$18→$8
Nov 10, 2025	BTIG	Mark Massaro	PT Raise	Buy	$13→$15
Nov 5, 2025	B. Riley Securities	Anderson Schock	PT Raise	Buy	$15→$18
Oct 27, 2025	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$11→$15
Oct 22, 2025	BTIG	Mark Massaro	PT Raise	Buy	$11→$13
Oct 14, 2025	Keybanc	Paul Knight	PT Raise	Overweight	$12→$15

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11

Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Exagen, Raises Price Target to $11

TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Exagen, Raises Price Target to $10

TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $10.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $12

B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $12.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Exagen, Raises Price Target to $9

BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $8 to $9.

Benzinga Newsdesk

PRO
Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8

Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk